Rebecca C. Hennessey

Rebecca C. Hennessey

Auto-generated profile, based on publicly available information

Rebecca C. Hennessey

Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, 20850, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2017 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
XGXiangnan Guan
Xiangnan Guan
KLKyle M. LaPak
Kyle M. LaPak
RHRebecca C. Hennessey
Rebecca C. Hennessey
CYChristina Y. Yu
Christina Y. Yu
RSReena Shakya
Reena Shakya
CBChristin E. Burd
Christin E. Burd
Senescent cells within the tumor microenvironment (TME) adopt a proinflammatory, senescence-associated secretory phenotype (SASP) that promotes cancer initiation, progression, and therapeutic resistance. Here, exposure to palbociclib (PD-0332991), a CDK4/6 inhibitor, induces senescence and a robust SASP in normal fibroblasts. Senescence caused by prolonged CDK4/6 inhibition is DNA damage–independent and associated with Mdm2 downregulation, whereas the SASP elicited by these cells is largely reliant upon NF-κB activation. Based upon these observations, it was hypothesized that the exposure of nontransformed stromal cells to PD-0332991 would promote tumor growth. Ongoing clinical trials of CDK4/6 inhibitors in melanoma prompted a validation of this hypothesis using a suite of genetically defined melanoma cells (i.e., Ras mutant, Braf mutant, and Ras/Braf wild-type). When cultured in the presence of CDK4/6i-induced senescent fibroblasts, melanoma cell lines exhibited genotype-dependent proliferative responses. However, in vivo, PD-0332991–treated fibroblasts enhanced the growth of all melanoma lines tested and promoted the recruitment of Gr-1–positive immune cells. These data indicate that prolonged CDK4/6 inhibitor treatment causes normal fibroblasts to enter senescence and adopt a robust SASP. Such senescent cells suppress the antitumor immune response and promote melanoma growth in immunocompetent, in vivo models. Implications: The ability of prolonged CDK4/6 inhibitor treatment to induce cellular senescence and a robust SASP in primary cells may hinder therapeutic efficacy and promote long-term, gerontogenic consequences that should be considered in clinical trials aiming to treat melanoma and other cancer types. Mol Cancer Res; 15(3); 237–49. ©2016 AACR.

4 July 2017 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
RHRebecca C. Hennessey
Rebecca C. Hennessey
AHAndrea M. Holderbaum
Andrea M. Holderbaum
ABAnamaria Bonilla
Anamaria Bonilla
CDConor Delaney
Conor Delaney
JGJames E. Gillahan
James E. Gillahan
CBChristin E. Burd
Christin E. Burd
Summary: To mitigate melanoma risk, sunscreen use is widely advocated; yet, the ability of sunscreens to prevent melanoma remains controversial. Here, we test the tenet that sunscreens limit melanoma risk by blocking ultraviolet radiation (UV)‐induced DNA damage using murine models that recapitulate the genetics and spontaneous evolution of human melanoma. We find that a single, non‐erythematous dose of UV dramatically accelerates melanoma onset and increases tumor multiplicity in mice carrying an endogenous, melanocyte‐specific NRas61R allele. By contrast, transient UV exposure does not alter tumor onset in mice lacking p16INK4a or harboring an NRas12D allele. To block the rapid onset of melanoma cooperatively caused by UV and NRas61R, we employed a variety of aerosol sunscreens. While all sunscreens delayed melanoma formation and blocked UV‐induced DNA damage, differences in aerosol output (i.e., amount applied/cm2) caused variability in the cancer preventative efficacy of products with identical sunburn protection factor (SPF) ratings.

1 March 2017 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
MFMatthew R. Farren
Matthew R. Farren
RHRebecca C. Hennessey
Rebecca C. Hennessey
RSReena Shakya
Reena Shakya
OEOmar Elnaggar
Omar Elnaggar
GYGregory Young
Gregory Young
GLGregory B. Lesinski
Gregory B. Lesinski
Selinexor, a selective inhibitor of nuclear export (SINE) compound targeting exportin-1, has previously been shown to inhibit melanoma cell growth in vivo. We hypothesized that combining selinexor with antibodies that block or disrupt T-cell checkpoint molecule signaling would exert superior antimelanoma activity. In vitro, selinexor increased PDCD1 and CTLA4 gene expression in leukocytes and induced CD274 gene expression in human melanoma cell lines. Mice bearing syngeneic B16F10 melanoma tumors demonstrated a significant reduction in tumor growth rate in response to the combination of selinexor and anti-PD-1 or anti-PD-L1 antibodies (P < 0.05). Similar results were obtained in B16F10-bearing mice treated with selinexor combined with anti-CTLA4 antibody. Immunophenotypic analysis of splenocytes by flow cytometry revealed that selinexor alone or in combination with anti-PD-L1 antibody significantly increased the frequency of both natural killer cells (P ≤ 0.050) and CD4+ T cells with a Th1 phenotype (P ≤ 0.050). Further experiments indicated that the antitumor effect of selinexor in combination with anti-PD-1 therapy persisted under an alternative dosing schedule but was lost when selinexor was administered daily. These data indicate that the efficacy of selinexor against melanoma may be enhanced by disrupting immune checkpoint activity. Mol Cancer Ther; 16(3); 417–27. ©2017 AACR. See related article by Tyler et al., p. 428.

27 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ENEmily Neil
Emily Neil
DPDongju Park
Dongju Park
RHRebecca C. Hennessey
Rebecca C. Hennessey
EDEric C. DiBiasio
Eric C. DiBiasio
MDMichael DiBuono
Michael DiBuono
ABAndreas Bosio
Andreas Bosio
Spatial Biology has evolved from the molecular characterization of microdissected cells to high throughput spatial RNA and protein expression analysis at scale. The main limitation of spatial technologies so far is the inability to resolve protein and RNA information in the same histological section. Here, we report for the first time the integration of highly multiplexed RNA and protein detection on the same tissue section. We developed a new, automated, spatial RNA detection method (RNAsky™), which is based on targeted rolling circle amplification and iterative staining. We combine RNAsky with MACSima™ Imaging Cyclic Staining (MICS) based protein analysis and show compatibility with subsequent standard hematoxylin and eosin (H&E) staining. Using both, open-source tools and our recently developed software suite MACS® iQ View, we demonstrate our multiomics MICS workflow by characterizing key immune-oncology markers at subcellular resolution across normal and diseased tissues.

3 April 2023
Verified
Other
Open access
MFMatthew R. Farren
Matthew R. Farren
RHRebecca C. Hennessey
Rebecca C. Hennessey
RSReena Shakya
Reena Shakya
OEOmar Elnaggar
Omar Elnaggar
GYGregory Young
Gregory Young
GLGregory B. Lesinski
Gregory B. Lesinski

4 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AOAidan O’BRien
Aidan O’BRien
HKHyunkyung Kong
Hyunkyung Kong
HPHarsh Patel
Harsh Patel
MHMichelle Ho
Michelle Ho
MPMinal B. Patel
Minal B. Patel
LALaufey T. Amundadottir
Laufey T. Amundadottir
Chromosome 5p15.33 harbors several independent association signals which demonstrate antagonistic pleiotropy across cancer types, with causal mechanisms largely unresolved. To identify functional variants and enhancer elements at this locus, we performed statistical fine-mapping followed by massively parallel reporter assays (MPRA) and proliferation based CRISPRi screens. This approach identified eight multi-cancer functional variants (MCFVs) across three GWAS signals. Targeting rs421629 (part of the CLPTM1L signal marked by rs465498) with CRISPRi revealed opposing effects on TERT expression in pancreatic versus lung cancer cells, consistent with the antagonistic pleiotropy observed for this signal. Furthermore, CRISPRi nominated an intronic CLPTM1L variable number tandem repeat (VNTR) as a potent enhancer. Long-read sequencing established VNTR polymorphisms as potential causal variants for the rs465498 signal. We showed that Hippo-pathway transcription factors mediate VNTR enhancer activity in lung and pancreatic cancer cells. Together, these findings indicate that cancer susceptibility at 5p15.33 may be mediated by both SNPs and VNTRs and provide an integrated framework for resolving complex pleiotropic loci.